# A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors

Source: https://onco.cc/trials/nct06848699/  
OnCo record `nct06848699` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Serplulimab in non-small-cell lung cancer and small-cell lung cancer, run by Shanghai Henlius Biotech, now recruiting.

## Summary

A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06848699 by Shanghai Henlius Biotech, with 105 participants planned, started 2025-02-25 and due to reach its primary completion in 2026-10-30. Interventions recorded: HLX43 dose 1, HLX43 dose 2, HLX43 dose 3, HLX43 dose 4, HLX43 dose 5. Conditions listed: Solid Tumor Cancer, Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06848699
- Phase: 1/2
- Setting: A Phase Ib/ II Clinical Study to Evaluate the Safety ,Torlerbility , and Efficacy of HLX43 (Anti-PD-L1 ADC) in Combination With Serplulimab (Anti-PD-1 Humanized Monocl ) in Patients With Advanced/Metastatic Solid Tumors
- Sponsor: Shanghai Henlius Biotech
- Enrolled: 105

## Sources

- ClinicalTrials.gov NCT06848699: https://clinicaltrials.gov/study/NCT06848699

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Serplulimab](https://onco.cc/drugs/serplulimab/)
- companies: [Shanghai Henlius Biotech](https://onco.cc/companies/henlius/)

---
JSON: https://onco.cc/api/v1/entities/nct06848699.json